Abstract:Objective To evaluate the efficacy and safety of Doxazosin combined with Drotaverine Hydrochloride in the treatment of lower ureteral calculi. Methods A total of 400 patients with lower ureteral calculi treated in the First People’s Hospital of Foshan, Guangdong Province from January 2017 to January 2020 were selected as study objects. They were divided into group A, B, C, and group D, according to treatment plans, with 100 patients in each group. All patients in four groups were routinely treated with Niaoshitong Pills; group A did not add any ureteral smooth muscle relaxant; group B was given Doxazosin, group C was given Trotaverine Hydrochloride, and group D was given Doxazosin combined and Drotaverine Hydrochloride. All patients were followed up for four weeks, and the stone excretion rate, stone excretion time, renal colic recurrence rate and the incidence of adverse reactions were compared among four groups. Results There were statistically significant differences in stone excretion rate, stone excretion time, and renal colic recurrence rate among four groups (P < 0.008). The stone excretion rate of group D was higher than that of group A and C, and renal colic recurrence rate was lower than that of group A and C; the stone excretion rate of group B was higher than that of group A, and renal colic recurrence rate was lower than that of group A, and the differences were statistically significant (P < 0.05). Pairwise comparison of stone excretion time among four groups showed statistical significance (P < 0.05). There were no significant differences in the incidence of adverse reactions among four groups (P > 0.05). Conclusion Doxazosin combined with Drotaverine Hydrochloride in the treatment of lower ureteral calculi has good efficacy and high safety, which is worthy of clinical application.
胡渊 李斌. 多沙唑嗪联合盐酸屈他维林治疗输尿管下段结石的效果[J]. 中国医药导报, 2022, 19(6): 81-84.
HU Yuan LI Bin . Effect of Doxazosin combined with Drotaverine Hydrochloride in the treatment of lower ureteral calculi#br#. 中国医药导报, 2022, 19(6): 81-84.